Longitudinal changes in metabolite levels in olanzapine versus placebo groups
REGRESSION, CORTEX, REMISSION, MRS
Among the 33 patients who completed longitudinal MRS acquisitions, demographic and baseline characteristics were comparable in the olanzapine (The absolute changes in metabolite levels at each site are detailed in Table Metabolite level change in olanzapine versus placebo groups, treatment-group x time interaction. When the estimates of the linear mixed-model were meta-analyzed, patients who switched to placebo showed a greater change with a decrease in myo-inositol in the dACC (SMD = 1.11; 95% CI = 0.20–2.01; Meta-analysis of metabolite level change in the dACC in olanzapine versus placebo groups. Estimates (Est.) are regression coefficients of time (in days) controlled for age and sex. A positive standardized mean difference indicates a metabolite level increase in the olanzapine group compared to the placebo group (i.e., a decrease in the placebo group compared to the olanzapine group). Abbreviations. Cho, glycerophosphocholine + phosphocholine; Cr, creatine + phosphocreatine; dACC, dorsal anterior cingulate cortex; Est., estimated regression coefficients (× 10In a sensitivity analysis restricted to patients who sustained remission during the follow-up (